The vertical integration removes a critical supply-chain risk for the BIM-IOL System's Phase 3 trials and potential commercialization. Monitor for any post-closing purchase price adjustments and the next quarterly update on cash runway impact.
Price Chart
Executive Summary
SpyGlass Pharma acquired 100% of Advanced Vision Science, Inc. (AVS) from Santen for $13M in cash, securing its IOL manufacturing supply chain for the Phase 3 BIM-IOL System and gaining capacity to develop premium lens options. The deal closed same-day and includes ongoing supply agreements with Santen and Bausch + Lomb, preserving AVS's existing revenue streams.
Key Facts
- Acquired 100% of AVS from Santen for $13M cash on October 1, 2026
- AVS was the existing supplier of IOLs for SpyGlass Pharma's Phase 3 BIM-IOL System trials
- AVS will continue manufacturing Eternity brand IOLs for Santen under an Amended Supply and Distribution Agreement
- AVS will continue licensing its glistening-free hydrophobic acrylic lens material to Bausch + Lomb for enVista IOL line
- Acquisition secures scalable commercial IOL manufacturing and enables development of premium lens options (toric, extended depth-of-focus)
- CEO stated the company expects to maintain its existing cash runway post-acquisition
Financial Impact
$13M cash acquisition of a key supplier; no revenue or earnings figures provided in the filing
Risk Factors
- Integration of AVS operations may introduce manufacturing delays or cost overruns
- The $13M cash outlay reduces SpyGlass's cash runway, though management claims it is maintained
- Phase 3 BIM-IOL System results remain the primary catalyst; acquisition does not change clinical or regulatory risk
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001778922-26-000049 |
| Exhibit: exhibit991-8kprx100126.htm | 0001778922-26-000049 |
| Document: 0001778922-26-000049-index-headers.html | 0001778922-26-000049 |
| Document: 0001778922-26-000049-index.html | 0001778922-26-000049 |
| Document: 0001778922-26-000049.txt | 0001778922-26-000049 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 8-K | $26.16 $27.71 | ▲ +5.93% | ▲ +5.40% | $29.50 (+12.79%) |
Oct 19, 2026 7d ago | Press Release | $24.60 $26.16 | ▲ +6.34% | ▲ +6.01% | $29.50 (+19.94%) |
Oct 1, 2026 25d ago | 8-K | $26.50 $24.92 | ▼ −5.96% | ▼ −6.70% | $29.50 (+11.34%) |
Oct 1, 2026 25d ago | Press Release | $26.50 $24.92 | ▼ −5.96% | ▼ −6.70% | $29.50 (+11.34%) |
May 14, 2026 23w ago | 8-K | $23.21 $22.24 | ▼ −4.18% | ▼ −4.12% | $29.50 (+27.12%) |
Mar 26, 2026 30w ago | Press Release | $22.61 $23.37 | ▲ +3.36% | ▲ +3.72% | $29.50 (+30.50%) |
Mar 9, 2026 33w ago | Press Release | $27.12 $26.82 | ▼ −1.11% | ▼ −0.92% | $29.50 (+8.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers